| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0168-8278(00)80216-0 |
| P698 | PubMed publication ID | 10782903 |
| P50 | author | Albert Pares | Q40418471 |
| Llorenç Caballería | Q56208424 | ||
| P2093 | author name string | J Rodés | |
| L Rodrigo | |||
| J Berenguer | |||
| M Bruguera | |||
| J Mercader | |||
| D Rodríguez-Martínez | |||
| A García-Plaza | |||
| R Velicia | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis | Q39514969 | ||
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis | Q42280172 | ||
| The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis | Q45024371 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. | Q54035457 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III. | Q54096014 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| Primary biliary cirrhosis | Q71742524 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up | Q72223002 | ||
| Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis | Q72255528 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC | Q72789964 | ||
| Primary biliary cirrhosis | Q73732260 | ||
| P433 | issue | 4 | |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 561-566 | |
| P577 | publication date | 2000-04-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | |
| P478 | volume | 32 |
| Q45069872 | A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis. |
| Q44825279 | A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results |
| Q50164465 | AIDS Cholangiopathy |
| Q38694174 | Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury? |
| Q28344126 | Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis |
| Q38456383 | Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system: a case series |
| Q92326834 | Cholestatic liver diseases: An era of emerging therapies |
| Q57111104 | Cholestatic liver diseases: new targets, new therapies |
| Q37182934 | Clinical features and management of primary biliary cirrhosis. |
| Q26772310 | Combination antiretroviral studies for patients with primary biliary cirrhosis |
| Q44487597 | Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis |
| Q35068031 | Current management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q28655881 | Cystic fibrosis related liver disease--another black box in hepatology |
| Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
| Q43641326 | Effect of sodium tauroursodeoxycholate on phalloidin-induced cholestasis in rats |
| Q37352458 | Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial |
| Q38849427 | Evidence-based clinical practice guidelines for liver cirrhosis 2015. |
| Q91642039 | Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies |
| Q37661371 | Experimental evidence on the immunopathogenesis of primary biliary cirrhosis |
| Q36119487 | Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy |
| Q53221825 | Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. |
| Q37629675 | Hepatic inflammation and progressive liver fibrosis in chronic liver disease |
| Q34992359 | Immune-mediated bile duct injury: The case of primary biliary cirrhosis |
| Q85224687 | Immunohistochemical Staining of Inflammatory Cells in Liver Biopsy Specimens of Patients With Autoimmune Hepatitis, Primary Biliary Cirrhosis, and Overlap SyndromesThe Authors’ Reply |
| Q46907665 | Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis |
| Q64069796 | Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials |
| Q37738636 | Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis |
| Q38059628 | Longitudinal cystic fibrosis care |
| Q79222550 | Management of primary biliary cirrhosis |
| Q35734498 | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease |
| Q34936618 | Medical and economic impact of autoimmune hepatitis |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q44277489 | Methotrexate therapy for primary biliary cirrhosis |
| Q46102659 | Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid |
| Q36197335 | Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. |
| Q45948727 | Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. |
| Q35573903 | Natural history of primary biliary cirrhosis. |
| Q44797529 | Natural history of pruritus in primary biliary cirrhosis |
| Q92565000 | Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics |
| Q26824664 | Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q89623998 | New treatments/targets for primary biliary cholangitis |
| Q45279435 | No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis |
| Q85522942 | Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study |
| Q28087211 | Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis |
| Q89538006 | Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges |
| Q46835520 | Patients and patience: the pitfalls of primary biliary cirrhosis trials |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q54390436 | Primary biliary cholangitis: new treatments for an old disease. |
| Q21202919 | Primary biliary cirrhosis |
| Q56854243 | Primary biliary cirrhosis |
| Q84230884 | Primary biliary cirrhosis |
| Q26853145 | Primary biliary cirrhosis and liver transplantation |
| Q35609106 | Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. |
| Q35573929 | Primary biliary cirrhosis: specific treatment |
| Q35573937 | Primary biliary cirrhosis: the future |
| Q44004769 | Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis |
| Q33745849 | Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis |
| Q42406650 | Recent developments in the management of idiopathic cholestatic liver disease |
| Q33730935 | Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant |
| Q35030826 | Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? |
| Q45074381 | Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment |
| Q34472336 | The autoimmunity of primary biliary cirrhosis and the clonal selection theory |
| Q35833175 | The diagnosis and treatment of primary biliary cirrhosis |
| Q36914332 | The unfinished business of primary biliary cirrhosis |
| Q34182672 | Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q34398020 | Treatment of primary biliary cirrhosis |
| Q64991757 | Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? |
| Q55190939 | Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. |
| Q43561664 | Ursodeooxycholic acid for primary biliary cirrhosis |
| Q44671802 | Ursodeoxycholic acid and histological progression in primary biliary cirrhosis |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24241945 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q73497916 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q44110703 | Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial |
| Q43659683 | Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future? |
| Q43623767 | Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future |
| Q44487653 | Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression |
| Q42551875 | Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy |
| Q24293659 | Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
| Q34515643 | Use of ursodeoxycholic acid in patients with liver disease |
Search more.